# Aelis Farma Reports Its 2025 Annual Financial Results and Confirms Its 2026 Outlook > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/aelis-farma-financial-results-2025-outlook/ > **Published:** 2026-03-30T15:04:42-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:34:52-04:00 > **Clinical Summary:** Review Aelis Farma financial results 2025 and their 2026 outlook focusing on cannabis use disorder treatment progress. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic [Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/)Cb1 Receptor[Addiction Medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/)Pharmaceutical DevelopmentWithdrawal Why This Matters Aelis Farma is developing AEF0117, a selective CB1 receptor negative allosteric modulator, representing a novel pharmacological approach to [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder. Their financial stability and pipeline progression directly impacts when clinicians might have access to the first FDA-approved medication specifically targeting problematic [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). Clinical Summary Aelis Farma continues development of AEF0117, which works by modulating CB1 receptors without blocking them completely, potentially reducing cannabis cravings and use without the adverse effects seen with full CB1 antagonists like rimonabant. The company’s 2026 outlook suggests continued clinical trial progression for [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), though specific efficacy data and trial timelines require monitoring. This represents part of a broader pharmaceutical interest in developing targeted treatments for cannabis use disorder as legalization expands. Dr. Caplan’s Take “We desperately need evidence-based treatments for cannabis use disorder, and AEF0117’s mechanism is genuinely interesting from a receptor pharmacology standpoint. However, until we see robust Phase II data, this remains a promising but unproven approach.” Clinical Perspective 🧠 Clinicians treating cannabis use disorder currently rely on behavioral interventions and off-label medications with limited efficacy. Monitor Aelis Farma’s [clinical trial results](https://cedclinic.com/cannabidiol-liver-enzyme-elevation-healthy-adults/), particularly any data on withdrawal symptoms, craving reduction, and long-term abstinence rates. The selective modulation approach may offer advantages over previous CB1 antagonist attempts, but proof-of-concept efficacy data will be crucial. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Aelis%20Farma%20Reports%20Its%202025%20Annual%20Financial%20Results%20and%20Confirms%20Its%202026%20Outl...%20%40drcaplan&url=https%3A//www.businesswire.com/news/home/20260330937820/en/Aelis-Farma-Reports-Its-2025-Annual-Financial-Results-and-Confirms-Its-2026-Outlook)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.businesswire.com/news/home/20260330937820/en/Aelis-Farma-Reports-Its-2025-Annual-Financial-Results-and-Confirms-Its-2026-Outlook)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Aelis%20Farma%20Reports%20Its%202025%20Annual%20Financial%20Results%20and%20Confirms%20Its%202026%20Outl...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.businesswire.com/news/home/20260330937820/en/Aelis-Farma-Reports-Its-2025-Annual-Financial-Results-and-Confirms-Its-2026-Outlook)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.businesswire.com/news/home/20260330937820/en/Aelis-Farma-Reports-Its-2025-Annual-Financial-Results-and-Confirms-Its-2026-Outlook](https://www.businesswire.com/news/home/20260330937820/en/Aelis-Farma-Reports-Its-2025-Annual-Financial-Results-and-Confirms-Its-2026-Outlook) Table of Contents - [FAQ](#FAQ)[What is Cannabis Use Disorder?](#What_is_Cannabis_Use_Disorder) - [What is the CB1 receptor and why is it important?](#What_is_the_CB1_receptor_and_why_is_it_important) - [How is addiction medicine addressing cannabis dependency?](#How_is_addiction_medicine_addressing_cannabis_dependency) - [What pharmaceutical developments are being pursued for cannabis addiction?](#What_pharmaceutical_developments_are_being_pursued_for_cannabis_addiction) - [Why is this considered notable clinical interest?](#Why_is_this_considered_notable_clinical_interest) - [Related](#Related) ## FAQ #### What is Cannabis Use Disorder? Cannabis Use Disorder is a medical condition characterized by problematic cannabis use leading to clinically significant impairment or distress. It involves tolerance, withdrawal symptoms, and inability to control or reduce cannabis consumption despite negative consequences. #### What is the CB1 receptor and why is it important? The CB1 receptor is the primary cannabinoid receptor in the brain that mediates the psychoactive effects of THC. It plays a crucial role in cannabis addiction and is a key target for developing treatments for Cannabis Use Disorder. #### How is addiction medicine addressing cannabis dependency? [Addiction medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/) specialists are developing comprehensive treatment approaches that combine behavioral therapies with potential pharmacological interventions. Current research focuses on medications that can help reduce cannabis cravings and withdrawal symptoms. #### What pharmaceutical developments are being pursued for cannabis addiction? Pharmaceutical companies are investigating CB1 receptor antagonists and other compounds that could help treat Cannabis Use Disorder. These medications aim to reduce the rewarding effects of cannabis and help patients maintain abstinence. #### Why is this considered notable clinical interest? Cannabis Use Disorder affects millions globally, yet effective pharmacological treatments remain limited. The emergence of new research and potential therapeutic targets represents significant progress in addressing this growing public health concern. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Aelis Farma Reports Its 2025 Annual Financial Results and Confirms Its 2026 Outlook”, “url”: “https://www.businesswire.com/news/home/20260330937820/en/Aelis-Farma-Reports-Its-2025-Annual-Financial-Results-and-Confirms-Its-2026-Outlook”, “datePublished”: “2026-03-30T16:01:05Z”, “about”: “aelis farma reports its 2025 annual”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Ask the Expert: What is Cannabis Use Disorder and Who is at Risk? – Addiction Policy Forum](https://cedclinic.com/cannabis-use-disorder-addiction-risk/) Understand cannabis use disorder, its risks, and current expert insights on treatment approaches. [Learn More](https://cedclinic.com/cannabis-use-disorder-addiction-risk/) [Pleopharma To Present New Data on Cannabis Withdrawal in Patients With …](https://cedclinic.com/pleopharma-to-present-new-data-on-cannabis-withdrawal-in-patients-with/) Explore emerging data on cannabis withdrawal treatments relevant to ongoing pharmaceutical developments. [Read Article](https://cedclinic.com/pleopharma-to-present-new-data-on-cannabis-withdrawal-in-patients-with/) [SYT-510 for Generalized Anxiety Disorder: Phase 2 Trial Dosing Initiated | Psychiatric Times](https://cedclinic.com/syt-510-for-generalized-anxiety-disorder-phase-2-trial-dosing-initiated-psychiatric-times/) Stay updated on [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) for novel treatments impacting psychiatric conditions including cannabis use disorder. [Discover More](https://cedclinic.com/syt-510-for-generalized-anxiety-disorder-phase-2-trial-dosing-initiated-psychiatric-times/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).